A U.S. court refused to dismiss a suit against ImClone Systems brought by Repligen Corp. and the Massachusetts Institute of Technology over patent rights for the cellular line used in creating Erbitux. ImClone sought dismissal on grounds the patents have expired. Repligen and MIT will seek compensation for the unlicensed use of the patented technology, the company said.

Full Story:

Related Summaries